FDA: The U.S. Food and Drug Administration today authorized use of Lixelle
Beta 2-microglobulin Apheresis Column, the first device to treat
dialysis-related amyloidosis (DRA).
Only good, independent and reliable information about health from experts.
Showing posts with label dialysis. Show all posts
Showing posts with label dialysis. Show all posts
Saturday, March 7, 2015
Thursday, January 22, 2015
Added benefit of sucroferric oxyhydroxide is not proven
IQWIG. Germany: Sucroferric oxyhydroxide (trade name Velphoro) has been approved since August 2014 for adults with chronic kidney disease on haemodialysis or peritoneal dialysis. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether in these cases the drug offers patients an added benefit over the appropriate comparator therapies. According to the findings, an added benefit is not proven because no suitable data were available.
Subscribe to:
Comments (Atom)